2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Diagnosis and treatment of acute coronary syndromes: a review
DL Bhatt, RD Lopes, RA Harrington - Jama, 2022 - jamanetwork.com
Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …
[HTML][HTML] Antiplatelet therapy after percutaneous coronary intervention
Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary …
Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …
exercising their clinical judgment, as well as in the determination and the implementation of …
Rivaroxaban in peripheral artery disease after revascularization
Background Patients with peripheral artery disease who have undergone lower-extremity
revascularization are at high risk for major adverse limb and cardiovascular events. The …
revascularization are at high risk for major adverse limb and cardiovascular events. The …
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of …
Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …
is recommended in the guidelines, thus completing the loop between clinical research …
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy …
Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …
[HTML][HTML] Ticagrelor or prasugrel in patients with acute coronary syndromes
S Schüpke, FJ Neumann, M Menichelli… - … England Journal of …, 2019 - Mass Medical Soc
Background The relative merits of ticagrelor as compared with prasugrel in patients with
acute coronary syndromes for whom invasive evaluation is planned are uncertain. Methods …
acute coronary syndromes for whom invasive evaluation is planned are uncertain. Methods …
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open …
M Gimbel, K Qaderdan, L Willemsen, R Hermanides… - The Lancet, 2020 - thelancet.com
Background Current guidelines recommend potent platelet inhibition with ticagrelor or
prasugrel in patients after an acute coronary syndrome. However, data about optimal …
prasugrel in patients after an acute coronary syndrome. However, data about optimal …